Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33589105.
- Also identified by DOI 10.1016/j.mcna.2020.09.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are considered 2 diseases on the same spectrum due to their many underlying similarities. In recent years, both diseases have witnessed both diagnostic and treatment advances, which shaped the way we manage them. In this article, the authors focus on different diagnostic modalities in GCA as well as the presence of different clinical phenotypes and the role of screening for aortic involvement. The authors also discuss traditional treatments and the role of evolving steroid-sparing agents in the management of both GCA and PMR.
Medical subject headings
- Giant Cell Arteritis
- Polymyalgia Rheumatica